Primary Biliary Cirrhosis

Sleisenger and Fordtran’s Gastrointestinal and Liver Disease- 2 Volume Set: Pathophysiology, Diagnosis, Management, Expert Consult Premium Edition - Enhanced Online Features and Print

Volumn , Issue , 2010, Pages 1477-1488

  Angulo, Paul ^a   Lindor, Keith D ^b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84898541674     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-6189-2.00089-5     Document Type: Chapter

References (98)

1. Invernizzi P., Selmi C., Mackay IR., et al. From bases to basis: Linking genetics to causation in primary biliary cirrhosis Clin Gastroenterol Hepatol 3 2005 401-410(Ref 19.)
2. Jackson H., Solaymani-Dodaran M., Card TR., et al. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: A population-based cohort study Hepatology 46 2007 1131-1137(Ref 45.)
3. Jacob DA., Neumann UP., Bahra M., et al. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients Clin Transplant 20 2006 211-220(Ref 80.)
4. Jones DE., Bhala N., Burt J., et al. Four year follow-up of fatigue in a geographically defined primary biliary cirrhosis cohort Gut 55 2006 536-541(Ref 31.)
5. Lazaridis KN., Juran BD., Boe GM., et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis Hepatology 46 2007 785-792(Ref 5.)
6. Mayo MJ., Handem I., Saldana S., et al. Sertraline as a first-line treatment for cholestatic pruritus Hepatology 45 2007 666-674(Ref 72.)
7. Menon KV., Angulo P., Weston S., et al. Bone disease in patients with primary biliary cirrhosis: Independent predictors and rate of progression J Hepatol 35 2001 316-323(Ref 58.)
8. Pares A., Caballeria J., Rodes J Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid Gastroenterology 130 2006 715-720(Ref 43.)
9. Poupon RE., Lindor KD., Pares A., et al. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis J Hepatol 39 2003 12-16(Ref 35.)
10. Prince M., James OFW The epidemiology of primary biliary cirrhosis Clin Liver Dis 7 2003 795-819(Ref 2.)
11. Zein CO., Angulo P., Lindor KD When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin Gastroenterol Hepatol 1 2003 89-95(Ref 32.)
12. Zein C., Jorgensen RA., Clarke B., et al. Alendronate improves bone mineral density in patients with PBC: A randomized placebo-controlled trial Hepatology 42 2005 762-771(Ref 67.)
13. Dahlan Y., Smith L., Simmonds D., et al. Pediatric-onset primary biliary cirrhosis Gastroenterology 125 2003 1476-1479.
14. Prince M., James OFW The epidemiology of primary biliary cirrhosis Clin Liver Dis 7 2003 795-819.
15. Kim WR., Lindor KD., Locke GR III., et al. Epidemiology and natural history of primary biliary cirrhosis in a U.S. community Gastroenterology 119 2000 1631-1636.
16. Watt FE., James OF., Jones DE Patterns of autoimmunity in primary biliary cirrhosis patients and their families: A population-based cohort study QJM 97 2004 397-406.
17. Lazaridis KN., Juran BD., Boe GM., et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis Hepatology 46 2007 785-792.
18. Koarada S., Wu Y., Fertig N., et al. Genetic control of autoimmunity: protection from diabetes, but spontaneous autoimmune biliary disease in a nonobese diabetic congenic strain J Immunol 173 2004 2315-2323.
19. Oertelt S., Lian ZX., Cheng CM., et al. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice J Immunol 177 2006 1655-1660.
20. Wakabayashi K., Lian ZX., Moritoki Y., et al. IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosis Hepatology 44 2006 1240-1249.
21. Leung PS., Quan C., Park O., et al. Immunization with a xenobiotic 6-bromohexanoate bovine serum albumin conjugate induces antimitochondrial antibodies J Immunol 170 2003 5326-5332.
22. Rieger R., Gershwin ME The X and why of xenobiotics in primary biliary cirrhosis J Autoimmun 28 2007 76-84.
23. Kikuchi K., Lian ZX., Yang GX., et al. Bacterial CpG induces hyper-IgM production in CD27(+) memory B cells in primary biliary cirrhosis Gastroenterology 128 2005 304-312.
24. Muratori L., Muratori P., Granito A., et al. The Western immunoblotting pattern of anti-mitochondrial antibodies is independent of the clinical expression of primary biliary cirrhosis Dig Liver Dis 37 2005 108-112.
25. Muratori P., Muratori L., Ferrari R., et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis Am J Gastroenterol 98 2003 431-437.
26. Vergani D., Bogdanos DP Positive markers in AMA-negative PBC. [comment, editorial] Am J Gastroenterol 98 2003 241-243.
27. Granito A., Muratori P., Muratori L., et al. Antinuclear antibodies giving the “multiple nuclear dots” or the “rim-like/membranous” patterns: Diagnostic accuracy for primary biliary cirrhosis Aliment Pharmacol Therap 24 2006 1575-1583.
28. Invernizzi P., Podda M., Battezzati PM., et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis J Hepatol 34 2001 366-372.
29. Miyachi K., Hankins RW., Matsushima H., et al. Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: A multicenter study J Autoimmun 20 2003 247-254.
30. Nakamura M., Kondo H., Mori T., et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis Hepatology 45 2007 118-127.
31. Invernizzi P., Selmi C., Mackay IR., et al. From bases to basis: Linking genetics to causation in primary biliary cirrhosis Clin Gastroenterol Hepatol 3 2005 401-410.
32. Donaldson PT., Baragiotta A., Heneghan MA., et al. HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: A large-scale study Hepatology 44 2006 667-674.
33. Mullarkey ME., Stevens AM., McDonnell WM., et al. Human leukocyte antigen class II alleles in Caucasian women with primary biliary cirrhosis Tissue Antigens 65 2005 199-205.
34. Liu HY., Deng AM., Zhou Y., et al. Analysis of HLA alleles polymorphism in Chinese patients with primary biliary cirrhosis Hepatobiliary Pancreat Dis Int 5 2006 129-132.
35. Invernizzi P., Battezzati PM., Crosignani A., et al. Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis J Hepatol 38 2003 401-406.
36. Abdulkarim AS., Petrovic LM., Kim WR., et al. Primary biliary cirrhosis: An infectious disease caused by Chlamydia pneumoniae? J Hepatol 40 2004 380-384.
37. Selmi C., Balkwill DL., Invernizzi P., et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium Hepatology 38 2003 1250-1257.
38. Xu L., Sakalian M., Shen Z., et al. Cloning the human beta retrovirus proviral genome from patients with primary biliary cirrhosis Hepatology 39 2004 151-156.
39. Medzhitov R., Janeway CA Jr How does the immune system distinguish self from nonself? Semin Immunol 12 2000 185-188.
40. Long SA., Quan C., van de Water J., et al. Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: Connecting xenobiotics with primary biliary cirrhosis J Immunol 167 2001 2956-2963.
41. Goldblatt J., Taylor PJS., Lipman T., et al. The true impact of fatigue in primary biliary cirrhosis: A population study Gastroenterology 122 2002 1235-1241.
42. Prince M., Chetwynd A., Newman W., et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: Follow-up for up to 28 years Gastroenterology 123 2002 1044-1051.
43. Jones DE., Bhala N., Burt J., et al. Four year follow-up of fatigue in a geographically defined primary biliary cirrhosis cohort Gut 55 2006 536-541.
44. Zein CO., Angulo P., Lindor KD When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin Gastroenterol Hepatol 1 2003 89-95.
45. Prince M., Chetwynd A., Craig JV., et al. Asymptomatic primary biliary cirrhosis: Clinical features, prognosis, and symptom progression in a large population based cohort Gut 53 2004 865-870.
46. Pares A., Caballeria L., Rodes J., et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: Results of a double-blind controlled multicentric trial J Hepatol 32 2000 561-566.
47. Poupon RE., Lindor KD., Pares A., et al. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis J Hepatol 39 2003 12-16.
48. Lindor KD., Jorgensen RA., Therneau TM., et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis Mayo Clin Proc 72 1997 1137-1140.
49. Corpechot C., Carrat F., Poupon R., et al. Primary biliary cirrhosis: Incidence and predictive factors of cirrhosis development in ursodiol-treated patients Gastroenterology 122 2002 652-658.
50. Serfaty L., De Leusse A., Rosmorduc O., et al. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: An observational study Hepatology 38 2003 203-209.
51. Lindor KD., Poupon R., Poupon RE., et al. Ursodeoxycholic acid for primary biliary cirrhosis Lancet 355 2000 657-658.
52. Poupon R., Lindor KD., Cauch-Dudek K., et al. Combined analysis of French, American and Canadian randomized controlled trials of ursodeoxycholic acid therapy in primary biliary cirrhosis Gastroenterology 113 1997 884-890.
53. Shi J., Wu C., Lin Y., et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: A meta-analysis of randomized controlled trials Am J Gastroenterol 101 2006 1529-1538.
54. Corpechot C., Carrat F., Bahr A., et al. The effect of ursodeoxycholic acid therapy on the natural history of primary biliary cirrhosis Gastroenterology 128 2005 297-203.
55. Pares A., Caballeria J., Rodes J Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid Gastroenterology 130 2006 715-720.
56. ter Borg PC., Schalm SW., Hansen BE., et al. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients Am J Gastroenterol l 2006 2044-2050.
57. Jackson H., Solaymani-Dodaran M., Card TR., et al. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: A population-based cohort study Hepatology 46 2007 1131-1137.
58. Papatheodoridis GV., Hadziyannis ES., Deutsch M., et al. Ursodeoxycholic acid for primary biliary cirrhosis: Final results of a 12-year, prospective, randomized, controlled trial Am J Gastroenterol 97 2002 2063-2070.
59. Combes B., Luketic VA., Peters MG., et al. Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis Am J Gastroenterol 99 2004 264-268.
60. Corpechot C., Poupon R Geotherapeutics of primary biliary cirrhosis: Bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom Hepatology 46 2007 963-965.
61. Rautiainen H., Karkkainen P., Karvonen AL., et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three-year randomized trial Hepatology 41 2005 747-752.
62. Angulo P., Jorgensen RA., Keach JC., et al. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid Hepatology 31 2000 318-323.
63. Hempfling W., Grunhage F., Dilger K., et al. Pharmacokinetics and pharmacodynamic action of budesonide in early-and late-stage primary biliary cirrhosis Hepatology 38 2003 196-102.
64. Combes B., Emerson SS., Flye NL., et al. Methotrexate (MX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis Hepatology 42 2005 1184-1193.
65. Talwalkar JA., Angulo P., Keach JC., et al. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid J Clin Gastroenterol 39 2005 168-171.
66. Meyers RP., Shaheen AA., Swain MG., et al. Rituximab for primary biliary cirrhosis (PBC) refractory to ursodeoxycholic acid (UDCA) Hepatology 46 2007 550A.
67. Leuschner M., Holtmeier J., Ackermann H., et al. The influence of sulindac on patients with primary biliary cirrhosis that respond incompletely to ursodeoxycholic acid: A pilot study Eur J Gastroenterol Hepatol 14 2002 1369-1376.
68. Mason AL., Farr GH., Xu L., et al. Pilot studies of single and combination of retroviral therapy in patients with primary biliary cirrhosis Am J Gastroenterol 99 2004 2348-2355.
69. Pares A., Guanabens N., Alvarez L., et al. Collagen type Ia1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis Hepatology 33 2001 554-560.
70. Menon KV., Angulo P., Weston S., et al. Bone disease in patients with primary biliary cirrhosis: Independent predictors and rate of progression J Hepatol 35 2001 316-323.
71. Springer JE., Cole DE., Rubin LA., et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis Gastroenterology 118 2000 145-151.
72. Lakatos LP., Bajnok E., Hegedus D., et al. Vitamin D receptor Bsm I, estrogen receptor alpha gene Pvu and Xba I and IL-1 receptor-antagonist gene VNRT polymorphism and bone mineral density in Hungarian patients with primary biliary cirrhosis Eur J Gastroenterol Hepatol 14 2002 733-740.
73. Vogel A., Strassburg GP., Manns MP Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis Hepatology 35 2002 126-131.
74. Lakatos LP., Bajnok E., Tornai I., et al. Insulin-like growth factor I (IGF-I) gene microsatellite repeat, collagen type Ia1 gene (COLIA 1) Sp1 polymorphism and bone disease in primary biliary cirrhosis Eur J Gastroenterol Hepatol 16 2004 753-759.
75. Menon KV., Angulo P., Boe G., et al. Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis Am J Gastroenterol 98 2003 889-892.
76. Levy C., Harnois DM., Angulo P., et al. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: Results of a pilot study Liver Int 25 2003 117-121.
77. Lindor KD., Jorgensen RA., Tiegs RD., et al. Etidronate for osteoporosis in primary biliary cirrhosis. A randomized trial J Hepatol 33 2000 878-882.
78. Guanabens N., Pares A., Ros I., et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis Am J Gastroenterol 98 2003 2268-2274.
79. Zein C., Jorgensen RA., Clarke B., et al. Alendronate improves bone mineral density in patients with PBC: A randomized placebo-controlled trial Hepatology 42 2005 762-771.
80. Greenspan SL., Bone HG., Ettinger MP., et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: A randomized trial Ann Intern Med 146 2007 326-339.
81. Longo M., Crosignani A., Battezzati PM., et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis Gut 51 2002 265-269.
82. Ritzel U., Leonhardt U., Nather M., et al. Simvastatin in primary biliary cirrhosis: Effects on serum lipids and distinct disease markers J Hepatol 36 2002 454-458.
83. Jones EA., Molenaar HA., Oosting J Ondansetron in the treatment of pruritus of cholestasis: A randomized controlled trial Hepatogastroenterology 54 2007 1196-1199.
84. Mayo MJ., Handem I., Saldana S., et al. Sertraline as a first-line treatment for cholestatic pruritus Hepatology 45 2007 666-674.
85. Lee J., Belanger A., Doucette JT., et al. Transplantation trends in primary biliary cirrhosis Clin Gastroenterol Hepatol 5 2007 1313-1315.
86. European liver transplant registryhttp://www.eltr.org/publi/index_rv.php3.
87. Kamath PS., Wiesner RH., Malinchoc M., et al. A model to predict survival in patients with end-stage liver disease Hepatology 33 2001 464-470.
88. Liermann-Garcia RF., Evangelista Garcia C., McMaster P., et al. Transplantation for primary biliary cirrhosis: Retrospective analysis of 400 patients in a single center Hepatology 33 2001 22-27.
89. Sanchez EQ., Levy MF., Goldstein RM., et al. The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation Transplantation 76 2003 1583-1588.
90. Sylvestre PB., Batts KP., Burgart LJ., et al. Recurrence of primary biliary cirrhosis after liver transplantation: Histologic estimate of incidence and natural history Liver Transpl 9 2003 1086-1093.
91. Neuberger J., Gunson B., Hubscher S., et al. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation Liver Transpl 10 2004 488-491.
92. Jacob DA., Neumann UP., Bahra M., et al. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients Clin Transplant 20 2006 211-220.
93. Charatcharoenwitthaya P., Pimentel S., Talwalkar JA., et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation Liver Transpl 13 2007 1236-1245.
94. Oertelt S., Rieger R., Selmin C., et al. A sensitive bead assay for antimitochondrial antibodies chipping away at AMA-negative primary biliary cirrhosis Hepatology 45 2007 659-665.
95. Heathcote EJ Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines Hepatology 31 2000 1005-1013.
96. Stone J., Wade JA., Cauch-Dudek K., et al. Human leukocyte antigen class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis J Hepatol 36 2002 8-13.
97. Lan RY., Cheng C., Lian ZX., et al. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis Hepatology 43 2006 729-737.
98. Gisbert JP., Jones EA., Pajares JM., et al. Review article. Is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)? Aliment Pharmacol Ther 17 2003 17-27.